Related Experiment Videos
[Chronic therapy with ursodeoxycholic acid in a child with Alagille syndrome]
C Clerici1, G Gentili, G Dozzini
1Istituto di Gastroenterologia ed Endoscopia Digestiva, Università degli Studi di Perugia, Italia.
Insights
Ursodeoxycholic acid therapy significantly improved cholestatic and hepatonecrotic indices in a boy with Alagille Syndrome. Symptoms like pruritus and steatorrhea resolved, showing potential benefits for children with this rare liver disorder.
Area of Science:
- Hepatology
- Pediatric Gastroenterology
- Pharmacology
Background:
- Alagille Syndrome is a genetic disorder characterized by congenital hypoplasia of intrahepatic bile ducts, leading to chronic cholestasis.
- Management of Alagille Syndrome often involves addressing complications of cholestasis and liver dysfunction.
- Ursodeoxycholic acid is a bile acid used to treat various cholestatic liver diseases.
Observation:
- A 10-year-old boy with Alagille Syndrome received oral ursodeoxycholic acid (10 mg/kg/day).
- Clinical and biochemical parameters of cholestasis and liver injury were monitored before, during, and after treatment.
- Liver biopsy was performed post-treatment to assess histological changes.
Findings:
- Ursodeoxycholic acid treatment resulted in marked and sustained improvement of cholestatic and hepatonecrotic indices.
- Patient experienced resolution of pruritus and steatorrhea during therapy.
- Liver histology showed disappearance of biliary plugs, though intrahepatic bile duct number did not increase.
Implications:
- Ursodeoxycholic acid demonstrates therapeutic potential in managing Alagille Syndrome, potentially improving outcomes and delaying liver transplantation.
- Long-term studies with larger patient cohorts are warranted to confirm efficacy and safety.
- This highlights the role of bile acid therapy in pediatric chronic cholestatic disorders.
Abstract:
The effectiveness of oral bile acid therapy with ursodeoxycholic acid (10 mg/kg/day) was investigated in a 10 year old boy affected by Alagille's Syndrome, a chronic cholestatic disorder due to congenital hypoplasia of the intrahepatic biliary ducts. Cholestatic and hepatonecrotic indices were measured before and during ursodeoxycholic acid therapy and 1 month after stopping and 36 months after restarting the treatment. Ursodeoxycholic acid led to a marked improvement in the cholestatic and hepatonecrotic parameters which was maintained during all the treatment phase. Pruritus and steatorrhea disappeared during the treatment with ursodeoxycholic acid. Histological examination of the liver biopsy after the treatment revealed a disappearance of the biliary plugs but without increasing he intrahepatic bile ducts. The results suggest that ursodeoxycholic acid may improve the condition of the children affected by Alagille's Syndrome, specially when the liver transplantation is required, and indicate a need for long term studies in a larger number of patients.